<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223768</url>
  </required_header>
  <id_info>
    <org_study_id>8-12-00 C</org_study_id>
    <nct_id>NCT01223768</nct_id>
  </id_info>
  <brief_title>Acetyl-L-Carnitine In Severe Hepatic Encephalopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catania</source>
  <brief_summary>
    <textblock>
      To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy
      (grade 3 of the West Haven grading scale), we performed a randomised, double blind
      placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on
      ammonia levels and performance in cognitive functions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>December 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)</condition>
  <arm_group>
    <arm_group_label>Acetyl-L-carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl-l-Carnitine</intervention_name>
    <description>2g per day</description>
    <arm_group_label>Acetyl-L-carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>twice per day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale)
             with hepatic cirrhosis

        Exclusion Criteria:

          -  Patients with a history of recent alcohol abuse, patients using psychotropic drugs
             (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and
             antidepressants)

          -  Other exclusion criteria were the following: major complications of portal
             hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial
             peritonitis; acute superimposed liver injury;patients with metabolic disorders such as
             diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage
             renal disease; any additional precipitating factors such as high protein intake
             (additional high-protein meals), constipation; illiteracy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cannizzaro Hospital</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

